{"product_id":"gdf-8-2mg","title":"GDF-8 2mg vial","description":"\u003cp class=\"\" data-end=\"988\" data-start=\"508\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                             \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN \u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eCONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"\" data-end=\"988\" data-start=\"508\"\u003e\u003cstrong data-end=\"551\" data-start=\"508\"\u003eGrowth Differentiation Factor-8 (GDF-8)\u003c\/strong\u003e, commonly known as \u003cstrong data-end=\"584\" data-start=\"571\"\u003eMyostatin\u003c\/strong\u003e, is a protein belonging to the transforming growth factor-beta (TGF-β) superfamily. Identified in 1997, myostatin is primarily known as a potent negative regulator of skeletal muscle growth. Genetic mutations or pharmacological inhibition of myostatin leads to remarkable increases in muscle mass, making it a focal point of research in treating muscle-wasting diseases and enhancing muscle performance.\u003c\/p\u003e\n\u003chr class=\"\" data-end=\"993\" data-start=\"990\"\u003e\n\u003ch2 class=\"\" data-end=\"1019\" data-start=\"995\"\u003eBiological Properties\u003c\/h2\u003e\n\u003cul data-end=\"1468\" data-start=\"1021\"\u003e\n\u003cli class=\"\" data-end=\"1079\" data-start=\"1021\"\u003e\n\u003cp class=\"\" data-end=\"1079\" data-start=\"1023\"\u003e\u003cstrong data-end=\"1037\" data-start=\"1023\"\u003eFull Name:\u003c\/strong\u003e Growth Differentiation Factor-8 (GDF-8)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"1147\" data-start=\"1080\"\u003e\n\u003cp class=\"\" data-end=\"1147\" data-start=\"1082\"\u003e\u003cstrong data-end=\"1093\" data-start=\"1082\"\u003eFamily:\u003c\/strong\u003e TGF-β (transforming growth factor-beta) superfamily\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"1206\" data-start=\"1148\"\u003e\n\u003cp class=\"\" data-end=\"1206\" data-start=\"1150\"\u003e\u003cstrong data-end=\"1159\" data-start=\"1150\"\u003eRole:\u003c\/strong\u003e Negative regulator of skeletal muscle growth\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"1334\" data-start=\"1207\"\u003e\n\u003cp class=\"\" data-end=\"1334\" data-start=\"1209\"\u003e\u003cstrong data-end=\"1224\" data-start=\"1209\"\u003eExpression:\u003c\/strong\u003e Predominantly expressed in skeletal muscle; also found at lower levels in adipose tissue and cardiac muscle\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"1468\" data-start=\"1335\"\u003e\n\u003cp class=\"\" data-end=\"1468\" data-start=\"1337\"\u003e\u003cstrong data-end=\"1361\" data-start=\"1337\"\u003eMechanism of Action:\u003c\/strong\u003e Acts through activin type-II receptors (ActRIIB), inhibiting muscle cell proliferation and differentiation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"\" data-end=\"1473\" data-start=\"1470\"\u003e\n\u003ch2 class=\"\" data-end=\"1497\" data-start=\"1475\"\u003eMechanism of Action\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"1562\" data-start=\"1499\"\u003eMyostatin functions primarily through the following mechanisms:\u003c\/p\u003e\n\u003ch3 class=\"\" data-end=\"1595\" data-start=\"1564\"\u003e1. Muscle Growth Inhibition\u003c\/h3\u003e\n\u003cul data-end=\"1835\" data-start=\"1596\"\u003e\n\u003cli class=\"\" data-end=\"1706\" data-start=\"1596\"\u003e\n\u003cp class=\"\" data-end=\"1706\" data-start=\"1598\"\u003eBinds to \u003cstrong data-end=\"1646\" data-start=\"1607\"\u003eactivin type II receptors (ActRIIB)\u003c\/strong\u003e on muscle cells, activating Smad2\/Smad3 signaling pathways.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"1835\" data-start=\"1707\"\u003e\n\u003cp class=\"\" data-end=\"1835\" data-start=\"1709\"\u003eSuppresses muscle hypertrophy by reducing satellite cell proliferation, differentiation, and fusion into mature muscle fibers.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 class=\"\" data-end=\"1876\" data-start=\"1837\"\u003e2. Regulation of Muscle Homeostasis\u003c\/h3\u003e\n\u003cul data-end=\"2010\" data-start=\"1877\"\u003e\n\u003cli class=\"\" data-end=\"2010\" data-start=\"1877\"\u003e\n\u003cp class=\"\" data-end=\"2010\" data-start=\"1879\"\u003eMaintains appropriate muscle mass and prevents excessive growth that could compromise metabolic efficiency and functional capacity.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 class=\"\" data-end=\"2048\" data-start=\"2012\"\u003e3. Crosstalk with Other Pathways\u003c\/h3\u003e\n\u003cul data-end=\"2159\" data-start=\"2049\"\u003e\n\u003cli class=\"\" data-end=\"2159\" data-start=\"2049\"\u003e\n\u003cp class=\"\" data-end=\"2159\" data-start=\"2051\"\u003eInteracts with other signaling pathways (IGF-1, mTOR, follistatin), modulating muscle metabolism and growth.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"\" data-end=\"2164\" data-start=\"2161\"\u003e\n\u003ch2 class=\"\" data-end=\"2229\" data-start=\"2166\"\u003eClinical Significance and Potential Therapeutic Applications\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"2316\" data-start=\"2231\"\u003eMyostatin inhibition is under intense research due to potential therapeutic benefits:\u003c\/p\u003e\n\u003ch3 class=\"\" data-end=\"2348\" data-start=\"2318\"\u003e1. Muscle-Wasting Diseases\u003c\/h3\u003e\n\u003cul data-end=\"2619\" data-start=\"2349\"\u003e\n\u003cli class=\"\" data-end=\"2486\" data-start=\"2349\"\u003e\n\u003cp class=\"\" data-end=\"2486\" data-start=\"2351\"\u003eTreatment of conditions like muscular dystrophy, cachexia, sarcopenia, and cancer-associated muscle wasting through myostatin blockade.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2619\" data-start=\"2487\"\u003e\n\u003cp class=\"\" data-end=\"2619\" data-start=\"2489\"\u003eClinical trials are exploring efficacy and safety of myostatin inhibitors (e.g., follistatin-based therapies, ActRIIB antibodies).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 class=\"\" data-end=\"2670\" data-start=\"2621\"\u003e2. Metabolic Disorders (Obesity and Diabetes)\u003c\/h3\u003e\n\u003cul data-end=\"2798\" data-start=\"2671\"\u003e\n\u003cli class=\"\" data-end=\"2798\" data-start=\"2671\"\u003e\n\u003cp class=\"\" data-end=\"2798\" data-start=\"2673\"\u003eImproved metabolic profile (enhanced insulin sensitivity, increased fat metabolism) observed with reduced myostatin activity.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 class=\"\" data-end=\"2843\" data-start=\"2800\"\u003e3. Age-Related Muscle Loss (Sarcopenia)\u003c\/h3\u003e\n\u003cul data-end=\"2916\" data-start=\"2844\"\u003e\n\u003cli class=\"\" data-end=\"2916\" data-start=\"2844\"\u003e\n\u003cp class=\"\" data-end=\"2916\" data-start=\"2846\"\u003eTherapeutic potential to reverse muscle decline associated with aging.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 class=\"\" data-end=\"2972\" data-start=\"2918\"\u003e4. Performance Enhancement (Experimental\/Athletic)\u003c\/h3\u003e\n\u003cul data-end=\"3125\" data-start=\"2973\"\u003e\n\u003cli class=\"\" data-end=\"3125\" data-start=\"2973\"\u003e\n\u003cp class=\"\" data-end=\"3125\" data-start=\"2975\"\u003ePotential misuse in sports and bodybuilding due to dramatic muscle hypertrophy and strength enhancement (strictly prohibited by anti-doping agencies).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"\" data-end=\"3130\" data-start=\"3127\"\u003e\n\u003ch2 class=\"\" data-end=\"3166\" data-start=\"3132\"\u003eMethods of Myostatin Inhibition\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"3255\" data-start=\"3168\"\u003eSeveral experimental and clinical approaches target myostatin to achieve muscle growth:\u003c\/p\u003e\n\u003cul data-end=\"3727\" data-start=\"3257\"\u003e\n\u003cli class=\"\" data-end=\"3376\" data-start=\"3257\"\u003e\n\u003cp class=\"\" data-end=\"3376\" data-start=\"3259\"\u003e\u003cstrong data-end=\"3274\" data-start=\"3259\"\u003eAntibodies:\u003c\/strong\u003e Monoclonal antibodies (e.g., Stamulumab, Landogrozumab) blocking myostatin from binding its receptor.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"3499\" data-start=\"3377\"\u003e\n\u003cp class=\"\" data-end=\"3499\" data-start=\"3379\"\u003e\u003cstrong data-end=\"3430\" data-start=\"3379\"\u003eSoluble Receptors (ActRIIB-Fc Fusion Proteins):\u003c\/strong\u003e Decoy receptors that sequester myostatin and related growth factors.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"3620\" data-start=\"3500\"\u003e\n\u003cp class=\"\" data-end=\"3620\" data-start=\"3502\"\u003e\u003cstrong data-end=\"3552\" data-start=\"3502\"\u003eFollistatin and Follistatin-Derived Molecules:\u003c\/strong\u003e Natural inhibitors of myostatin; gene therapies currently explored.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"3727\" data-start=\"3621\"\u003e\n\u003cp class=\"\" data-end=\"3727\" data-start=\"3623\"\u003e\u003cstrong data-end=\"3654\" data-start=\"3623\"\u003eGene Editing (CRISPR\/Cas9):\u003c\/strong\u003e Experimental genetic knockout or knockdown of myostatin gene expression.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"\" data-end=\"3732\" data-start=\"3729\"\u003e\n\u003ch2 class=\"\" data-end=\"3785\" data-start=\"3734\"\u003eDosage and Administration (Experimental Context)\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"3936\" data-start=\"3787\"\u003eAs myostatin inhibitors remain experimental, no approved standard dosing guidelines exist. Typical experimental dosing from clinical trials includes:\u003c\/p\u003e\n\u003cul data-end=\"4335\" data-start=\"3938\"\u003e\n\u003cli class=\"\" data-end=\"4063\" data-start=\"3938\"\u003e\n\u003cp class=\"\" data-end=\"3987\" data-start=\"3940\"\u003e\u003cstrong data-end=\"3985\" data-start=\"3940\"\u003eMonoclonal Antibodies (e.g., Stamulumab):\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-end=\"4063\" data-start=\"3990\"\u003e\n\u003cli class=\"\" data-end=\"4060\" data-start=\"3990\"\u003e\n\u003cp class=\"\" data-end=\"4060\" data-start=\"3992\"\u003e10–30 mg\/kg intravenously every 4–8 weeks (clinical trial contexts).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"4208\" data-start=\"4064\"\u003e\n\u003cp class=\"\" data-end=\"4099\" data-start=\"4066\"\u003e\u003cstrong data-end=\"4097\" data-start=\"4066\"\u003eActRIIB-Fc Fusion Proteins:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-end=\"4208\" data-start=\"4102\"\u003e\n\u003cli class=\"\" data-end=\"4208\" data-start=\"4102\"\u003e\n\u003cp class=\"\" data-end=\"4208\" data-start=\"4104\"\u003eVaried dosages: typically 1–10 mg\/kg subcutaneously or intravenously every 1–4 weeks in clinical trials.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"4335\" data-start=\"4210\"\u003e\n\u003cp class=\"\" data-end=\"4256\" data-start=\"4212\"\u003e\u003cstrong data-end=\"4254\" data-start=\"4212\"\u003eGene Therapy (Follistatin Expression):\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-end=\"4335\" data-start=\"4259\"\u003e\n\u003cli class=\"\" data-end=\"4335\" data-start=\"4259\"\u003e\n\u003cp class=\"\" data-end=\"4335\" data-start=\"4261\"\u003eSingle-dose intramuscular injection, varying according to trial protocols.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"\" data-end=\"4480\" data-start=\"4337\"\u003e\u003cstrong data-end=\"4346\" data-start=\"4337\"\u003eNote:\u003c\/strong\u003e All myostatin inhibition strategies remain investigational; dosing and safety have not yet been established for general clinical use.\u003c\/p\u003e\n\u003chr class=\"\" data-end=\"4485\" data-start=\"4482\"\u003e\n\u003ch2 class=\"\" data-end=\"4521\" data-start=\"4487\"\u003eSafety Profile and Side Effects\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"4623\" data-start=\"4523\"\u003eClinical trials indicate potential side effects and safety considerations with myostatin inhibition:\u003c\/p\u003e\n\u003ch3 class=\"\" data-end=\"4660\" data-start=\"4625\"\u003eCommonly Reported Side Effects:\u003c\/h3\u003e\n\u003cul data-end=\"4750\" data-start=\"4661\"\u003e\n\u003cli class=\"\" data-end=\"4709\" data-start=\"4661\"\u003e\n\u003cp class=\"\" data-end=\"4709\" data-start=\"4663\"\u003eMild injection-site reactions (pain, erythema)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"4750\" data-start=\"4710\"\u003e\n\u003cp class=\"\" data-end=\"4750\" data-start=\"4712\"\u003eIncreased muscle stiffness or soreness\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 class=\"\" data-end=\"4785\" data-start=\"4752\"\u003ePotential Risks and Concerns:\u003c\/h3\u003e\n\u003cul data-end=\"5385\" data-start=\"4786\"\u003e\n\u003cli class=\"\" data-end=\"4948\" data-start=\"4786\"\u003e\n\u003cp class=\"\" data-end=\"4818\" data-start=\"4788\"\u003e\u003cstrong data-end=\"4816\" data-start=\"4788\"\u003eTendon and Joint Issues:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-end=\"4948\" data-start=\"4821\"\u003e\n\u003cli class=\"\" data-end=\"4945\" data-start=\"4821\"\u003e\n\u003cp class=\"\" data-end=\"4945\" data-start=\"4823\"\u003eAnimal models suggest increased risk of tendon rupture or joint injury due to disproportionate muscle growth and strength.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"5077\" data-start=\"4949\"\u003e\n\u003cp class=\"\" data-end=\"4973\" data-start=\"4951\"\u003e\u003cstrong data-end=\"4971\" data-start=\"4951\"\u003eCardiac Effects:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-end=\"5077\" data-start=\"4976\"\u003e\n\u003cli class=\"\" data-end=\"5074\" data-start=\"4976\"\u003e\n\u003cp class=\"\" data-end=\"5074\" data-start=\"4978\"\u003ePotential unknown long-term effects on cardiac muscle and function; animal data suggest caution.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"5267\" data-start=\"5078\"\u003e\n\u003cp class=\"\" data-end=\"5104\" data-start=\"5080\"\u003e\u003cstrong data-end=\"5102\" data-start=\"5080\"\u003eMetabolic Effects:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-end=\"5267\" data-start=\"5107\"\u003e\n\u003cli class=\"\" data-end=\"5264\" data-start=\"5107\"\u003e\n\u003cp class=\"\" data-end=\"5264\" data-start=\"5109\"\u003eUnclear impact on long-term metabolic homeostasis; transient insulin sensitivity improvements observed, but longer-term metabolic impacts remain uncertain.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"5385\" data-start=\"5268\"\u003e\n\u003cp class=\"\" data-end=\"5310\" data-start=\"5270\"\u003e\u003cstrong data-end=\"5308\" data-start=\"5270\"\u003eImmune and Inflammatory Reactions:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-end=\"5385\" data-start=\"5313\"\u003e\n\u003cli class=\"\" data-end=\"5385\" data-start=\"5313\"\u003e\n\u003cp class=\"\" data-end=\"5385\" data-start=\"5315\"\u003eTheoretical risk of immune-mediated reactions with antibody therapies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"\" data-end=\"5390\" data-start=\"5387\"\u003e\n\u003ch2 class=\"\" data-end=\"5428\" data-start=\"5392\"\u003eContraindications and Precautions\u003c\/h2\u003e\n\u003cul data-end=\"5779\" data-start=\"5430\"\u003e\n\u003cli class=\"\" data-end=\"5618\" data-start=\"5430\"\u003e\n\u003cp class=\"\" data-end=\"5456\" data-start=\"5432\"\u003e\u003cstrong data-end=\"5454\" data-start=\"5432\"\u003eContraindications:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-end=\"5618\" data-start=\"5459\"\u003e\n\u003cli class=\"\" data-end=\"5561\" data-start=\"5459\"\u003e\n\u003cp class=\"\" data-end=\"5561\" data-start=\"5461\"\u003ePatients with cardiac conditions, severe musculoskeletal disorders, or compromised tendon integrity.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"5618\" data-start=\"5564\"\u003e\n\u003cp class=\"\" data-end=\"5618\" data-start=\"5566\"\u003ePregnancy or breastfeeding (unknown safety profile).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"5779\" data-start=\"5620\"\u003e\n\u003cp class=\"\" data-end=\"5640\" data-start=\"5622\"\u003e\u003cstrong data-end=\"5638\" data-start=\"5622\"\u003ePrecautions:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-end=\"5779\" data-start=\"5643\"\u003e\n\u003cli class=\"\" data-end=\"5711\" data-start=\"5643\"\u003e\n\u003cp class=\"\" data-end=\"5711\" data-start=\"5645\"\u003eCareful monitoring required for signs of tendon or joint injuries.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"5779\" data-start=\"5714\"\u003e\n\u003cp class=\"\" data-end=\"5779\" data-start=\"5716\"\u003eLong-term monitoring of cardiac function recommended in trials.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"\" data-end=\"5784\" data-start=\"5781\"\u003e\n\u003ch2 class=\"\" data-end=\"5816\" data-start=\"5786\"\u003eLegal and Regulatory Status\u003c\/h2\u003e\n\u003cul data-end=\"6091\" data-start=\"5818\"\u003e\n\u003cli class=\"\" data-end=\"5962\" data-start=\"5818\"\u003e\n\u003cp class=\"\" data-end=\"5842\" data-start=\"5820\"\u003e\u003cstrong data-end=\"5840\" data-start=\"5820\"\u003eApproval Status:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-end=\"5962\" data-start=\"5845\"\u003e\n\u003cli class=\"\" data-end=\"5962\" data-start=\"5845\"\u003e\n\u003cp class=\"\" data-end=\"5962\" data-start=\"5847\"\u003eCurrently, no myostatin inhibitor is FDA-approved for general clinical use. Several are in ongoing clinical trials.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"6091\" data-start=\"5963\"\u003e\n\u003cp class=\"\" data-end=\"5994\" data-start=\"5965\"\u003e\u003cstrong data-end=\"5992\" data-start=\"5965\"\u003eSports and Anti-Doping:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-end=\"6091\" data-start=\"5997\"\u003e\n\u003cli class=\"\" data-end=\"6091\" data-start=\"5997\"\u003e\n\u003cp class=\"\" data-end=\"6091\" data-start=\"5999\"\u003eExplicitly banned by WADA (World Anti-Doping Agency) due to performance-enhancing potential.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"\" data-end=\"6096\" data-start=\"6093\"\u003e\n\u003ch2 class=\"\" data-end=\"6137\" data-start=\"6098\"\u003eCurrent Research Status and Evidence\u003c\/h2\u003e\n\u003cul data-end=\"6542\" data-start=\"6139\"\u003e\n\u003cli class=\"\" data-end=\"6288\" data-start=\"6139\"\u003e\n\u003cp class=\"\" data-end=\"6288\" data-start=\"6141\"\u003ePreclinical and early clinical trials indicate promising potential for myostatin inhibitors in muscle-wasting disorders and age-related sarcopenia.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"6415\" data-start=\"6289\"\u003e\n\u003cp class=\"\" data-end=\"6415\" data-start=\"6291\"\u003eMixed outcomes reported in some human trials, necessitating further investigation into efficacy, safety, and optimal dosing.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"6542\" data-start=\"6416\"\u003e\n\u003cp class=\"\" data-end=\"6542\" data-start=\"6418\"\u003eSeveral agents (follistatin gene therapies, monoclonal antibodies, fusion proteins) actively undergoing clinical evaluation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"\" data-end=\"6547\" data-start=\"6544\"\u003e\n\u003ch2 class=\"\" data-end=\"6591\" data-start=\"6549\"\u003eSummary of Potential Benefits and Risks\u003c\/h2\u003e\n\u003cdiv class=\"group pointer-events-none relative flex justify-center *:pointer-events-auto\"\u003e\n\u003cspan data-state=\"closed\" class=\"pointer-events-none absolute start-full top-4 z-10 hidden h-full w-fit ps-2 md:block\"\u003e\u003cbutton class=\"hover:bg-token-main-surface-secondary text-token-text-secondary pointer-events-auto rounded-lg px-1 py-1 opacity-0 transition-opacity duration-200 group-focus-within:opacity-100 group-hover:opacity-100\"\u003e\u003csvg class=\"icon-md-heavy\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" fill=\"none\" viewbox=\"0 0 24 24\" height=\"24\" width=\"24\"\u003e\u003cpath fill=\"currentColor\" d=\"M7 5C7 3.34315 8.34315 2 10 2H19C20.6569 2 22 3.34315 22 5V14C22 15.6569 20.6569 17 19 17H17V19C17 20.6569 15.6569 22 14 22H5C3.34315 22 2 20.6569 2 19V10C2 8.34315 3.34315 7 5 7H7V5ZM9 7H14C15.6569 7 17 8.34315 17 10V15H19C19.5523 15 20 14.5523 20 14V5C20 4.44772 19.5523 4 19 4H10C9.44772 4 9 4.44772 9 5V7ZM5 9C4.44772 9 4 9.44772 4 10V19C4 19.5523 4.44772 20 5 20H14C14.5523 20 15 19.5523 15 19V10C15 9.44772 14.5523 9 14 9H5Z\" clip-rule=\"evenodd\" fill-rule=\"evenodd\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\u003c\/button\u003e\u003c\/span\u003e\n\u003cdiv class=\"tableContainer horzScrollShadows relative\"\u003e\n\u003ctable data-end=\"7276\" data-start=\"6593\" class=\"min-w-full\"\u003e\n\u003cthead data-end=\"6705\" data-start=\"6593\"\u003e\n\u003ctr data-end=\"6705\" data-start=\"6593\"\u003e\n\u003cth data-end=\"6643\" data-start=\"6593\"\u003e\u003cstrong data-end=\"6617\" data-start=\"6595\"\u003ePotential Benefits\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-end=\"6705\" data-start=\"6643\"\u003e\u003cstrong data-end=\"6680\" data-start=\"6645\"\u003ePotential Risks and Limitations\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"7276\" data-start=\"6819\"\u003e\n\u003ctr data-end=\"6932\" data-start=\"6819\"\u003e\n\u003ctd data-end=\"6871\" data-start=\"6819\" class=\"max-w-[calc(var(--thread-content-max-width)*2\/3)] min-w-[calc(var(--thread-content-max-width)\/3)]\"\u003eDramatic muscle hypertrophy and strength increase\u003c\/td\u003e\n\u003ctd data-end=\"6932\" data-start=\"6871\" class=\"max-w-[calc(var(--thread-content-max-width)*2\/3)] min-w-[calc(var(--thread-content-max-width)\/3)]\"\u003eTendon and joint injury risks (disproportionate growth)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7048\" data-start=\"6933\"\u003e\n\u003ctd data-end=\"6986\" data-start=\"6933\" class=\"max-w-[calc(var(--thread-content-max-width)*2\/3)] min-w-[calc(var(--thread-content-max-width)\/3)]\"\u003eTherapeutic potential in muscle-wasting conditions\u003c\/td\u003e\n\u003ctd data-end=\"7048\" data-start=\"6986\" class=\"max-w-[calc(var(--thread-content-max-width)*2\/3)] min-w-[calc(var(--thread-content-max-width)\/3)]\"\u003eUnknown long-term cardiac and metabolic safety profiles\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7162\" data-start=\"7049\"\u003e\n\u003ctd data-end=\"7100\" data-start=\"7049\" class=\"max-w-[calc(var(--thread-content-max-width)*2\/3)] min-w-[calc(var(--thread-content-max-width)\/3)]\"\u003eImproved metabolic health (insulin sensitivity)\u003c\/td\u003e\n\u003ctd data-end=\"7162\" data-start=\"7100\" class=\"max-w-[calc(var(--thread-content-max-width)*2\/3)] min-w-[calc(var(--thread-content-max-width)\/3)]\"\u003eImmune or inflammatory responses with antibody therapies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7276\" data-start=\"7163\"\u003e\n\u003ctd data-end=\"7214\" data-start=\"7163\" class=\"max-w-[calc(var(--thread-content-max-width)*2\/3)] min-w-[calc(var(--thread-content-max-width)\/3)]\"\u003eBeneficial in combating age-related muscle loss\u003c\/td\u003e\n\u003ctd data-end=\"7276\" data-start=\"7214\" class=\"max-w-[calc(var(--thread-content-max-width)*2\/3)] min-w-[calc(var(--thread-content-max-width)\/3)]\"\u003eCurrently experimental; no approved therapies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr class=\"\" data-end=\"7281\" data-start=\"7278\"\u003e\n\u003ch2 class=\"\" data-end=\"7322\" data-start=\"7283\"\u003eFuture Directions and Research Needs\u003c\/h2\u003e\n\u003cul data-end=\"7661\" data-start=\"7324\"\u003e\n\u003cli class=\"\" data-end=\"7457\" data-start=\"7324\"\u003e\n\u003cp class=\"\" data-end=\"7457\" data-start=\"7326\"\u003eCompletion of large-scale, randomized controlled trials (RCTs) to establish clinical efficacy, optimal dosage, and safety profiles.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"7552\" data-start=\"7458\"\u003e\n\u003cp class=\"\" data-end=\"7552\" data-start=\"7460\"\u003eClarification of long-term impacts on musculoskeletal, cardiovascular, and metabolic health.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"7661\" data-start=\"7553\"\u003e\n\u003cp class=\"\" data-end=\"7661\" data-start=\"7555\"\u003eDevelopment of safer myostatin-modulating therapies with balanced muscle growth and fewer adverse effects.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"\" data-end=\"7666\" data-start=\"7663\"\u003e\n\u003ch2 class=\"\" data-end=\"7681\" data-start=\"7668\"\u003eConclusion\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"8132\" data-start=\"7683\"\u003eGDF-8 (\u003cstrong data-end=\"7703\" data-start=\"7690\"\u003eMyostatin\u003c\/strong\u003e) represents a significant target in muscular biology, offering profound implications for treating muscle-wasting conditions and potentially enhancing metabolic health. Despite its exciting therapeutic potential, extensive research is necessary to fully characterize long-term risks, optimize safe and effective dosing strategies, and establish regulatory approval. Myostatin inhibitors currently remain strictly investigational.\u003c\/p\u003e\n\u003chr class=\"\" data-end=\"8137\" data-start=\"8134\"\u003e\n\u003ch2 class=\"\" data-end=\"8172\" data-start=\"8139\"\u003eReferences \u003c\/h2\u003e\n\u003cul data-end=\"8655\" data-start=\"8174\"\u003e\n\u003cli class=\"\" data-end=\"8297\" data-start=\"8174\"\u003e\n\u003cp class=\"\" data-end=\"8297\" data-start=\"8176\"\u003eLee, S.J. (2004). \"Regulation of muscle mass by myostatin.\" \u003cem data-end=\"8285\" data-start=\"8236\"\u003eAnnual Review of Cell and Developmental Biology\u003c\/em\u003e, 20, 61–86.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"8481\" data-start=\"8298\"\u003e\n\u003cp class=\"\" data-end=\"8481\" data-start=\"8300\"\u003eAmthor, H., \u0026amp; Hoogaars, W.M.H. (2012). \"Interference with myostatin\/ActRIIB signaling as a therapeutic strategy for neuromuscular disorders.\" \u003cem data-end=\"8464\" data-start=\"8442\"\u003eCurrent Gene Therapy\u003c\/em\u003e, 12(3), 245–259.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"8655\" data-start=\"8482\"\u003e\n\u003cp class=\"\" data-end=\"8655\" data-start=\"8484\"\u003eCohen, S., Nathan, J.A., \u0026amp; Goldberg, A.L. (2015). \"Muscle wasting in disease: molecular mechanisms and promising therapies.\" \u003cem data-end=\"8640\" data-start=\"8609\"\u003eNature Reviews Drug Discovery\u003c\/em\u003e, 14(1), 58–74.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"\" data-end=\"8922\" data-start=\"8662\"\u003e\u003cstrong data-end=\"8677\" data-start=\"8662\"\u003eDisclaimer:\u003c\/strong\u003e\u003cbr data-end=\"8680\" data-start=\"8677\"\u003eThis product is strictly educational. Myostatin inhibitors are experimental therapies and not approved for general clinical use. Always consult qualified healthcare providers before exploring experimental treatments or therapies.\u003c\/p\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684860817746,"sku":"10","price":100.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/gdf-8_2mg.png?v=1770834907","url":"https:\/\/sciencepeptideslab.com\/products\/gdf-8-2mg","provider":"Science Peptides Lab","version":"1.0","type":"link"}